A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a preclinical-stage synthetic allogeneic iMSC therapy company. iMSCs are induced pluripotent stem cell (“iPSC”)-derived mesenchymal stem cells. We envision a future where cell therapies powered by synthetic iMSCs can offer new options for patients with limited treatment paths and our mission is to transform the treatment of cancer and autoimmune disease by developing scalable, affordable, off-the-shelf cell therapies that restore hope. Objectives and Business Strategy Our lead product candidate ERNA-101 is allogenic IL-7 and IL-15-secreting iMSCs. ERNA-101 capitalizes on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (“TME”), limiting systemic exposure and potential toxicity while potentially unleashing potent anti-cancer immune responses including enhancement of T-cell anti-tumor activity.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | 582K | - | 0 | 5.8M |
| Net Income | -14M | -14M | - | -22M | -25M | -7.3M |
| EPS | $-2.24 | $-2.24 | $-734.40 | $-61.20 | $-120.90 | $-906.00 |
| Free Cash Flow | -7.1M | -7.1M | -16M | -20M | -21M | -8.3M |
| ROIC | -731.1% | -126.2% | - | -34.0% | -130.8% | -51.6% |
| Gross Margin | - | - | 83.5% | - | - | 73.5% |
| Debt/Equity | 0.20 | 0.20 | 6.79 | 4.87 | 0.44 | 0.55 |
| Dividends/Share | $0.00 | - | - | $0.00 | $0.08 | $0.00 |
| Operating Income | -9.3M | -9.3M | -16M | -21M | -33M | -7.2M |
| Operating Margin | 0.0% | - | -2693.1% | - | - | -125.0% |
| ROE | -587.3% | -687.5% | - | -971.1% | -130.8% | -83.8% |
| Shares Outstanding | 29M | 29M | 2M | 3M | 0M | 0M |
Ernexa Therapeutics Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 78.5%.
Ernexa Therapeutics Inc. (ERNA) has a 5-year average return on invested capital (ROIC) of -85.6%. This is below average and may indicate limited pricing power.
Ernexa Therapeutics Inc. (ERNA) has a market capitalization of $6M. It is classified as a small-cap stock.
Ernexa Therapeutics Inc. (ERNA) does not currently pay a regular dividend.
Ernexa Therapeutics Inc. (ERNA) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Ernexa Therapeutics Inc. (ERNA) generated $-7 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Ernexa Therapeutics Inc. (ERNA) has a debt-to-equity ratio of 0.20. This indicates a conservatively financed balance sheet.
Ernexa Therapeutics Inc. (ERNA) reported earnings per share (EPS) of $-2.24 in its most recent fiscal year.
Ernexa Therapeutics Inc. (ERNA) has a return on equity (ROE) of -687.5%. A negative ROE may indicate losses or negative equity.
Ernexa Therapeutics Inc. (ERNA) has a 5-year average gross margin of 78.5%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 15 years of financial data for Ernexa Therapeutics Inc. (ERNA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Ernexa Therapeutics Inc. (ERNA) has a book value per share of $0.08, based on its most recent annual SEC filing.